Marker Therapeutics Inc (MRKR)

[Rkmatters]

Because one in a further along phase is undervalued it doesn't make one in an earlier phase overvalued. Market sentiment drives opportunity sometimes. Certain companies are down because of supply/demand interest and no supporting shareholder base as that can often come along with institutional interest which very much is dependent on how the overall biotech industry sees that drug or biologicals prospects. Big Pharma could be waiting for successfully phase III study on the biotech before making some kind of M&A offer (partnerships count). And then the biotechs themselves will have different potential valuations based on how much money they can bring in yearly based on success. For instance in a portion of the HER-2 Herceptin brings in $5 billion a year. And so you have to weigh market relatively. Perhaps the study you reference can combined expect to see sales on their two drugs that don't even remotely equal the potential of TPIV one vaccine in one indication. So to compare companies on simple market valuations is faulty. But yes, one might be the better position for explosive growth in a shorter time frame if it sees success. Lots goes into the picture. It's never a market cap to market cap judgement evaluation, you might be looking at apples and watermelons. :)